Multicenter real-world outcomes in limited stage (LS) diffuse large B-cell lymphoma (DLBCL) treated with abbreviated immunochemotherapy
Journal
Blood
Topics
Lymphoma Diagnosis and Treatment
article
Multicenter real-world outcomes in limited stage (LS) diffuse large B-cell lymphoma (DLBCL) treated with abbreviated immunochemotherapy
article en
Abstract
No abstract available for this paper.
Publication Tag
BloodVol. 146(Supplement 1)
Institutions
Rutgers, The State University of New Jersey (US), Mayo Clinic (US), The University of Texas MD Anderson Cancer Center (US), Oregon Health & Science University (US), University of California, San Francisco (US), University of California, Irvine (US), University of Utah (US), Columbia University Irving Medical Center (US), University of Rochester Medical Center (US), Moffitt Cancer Center (US), Blood Systems Research Institute (US), MUSC Hollings Cancer Center (US), University of California, Irvine Medical Center (US), Levine Cancer Institute (US), City of Hope (US), Dana-Farber Cancer Institute (US), VA Long Beach Healthcare System (US), Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Saint Louis University (US), The Ohio State University (US), University of Pennsylvania (US), University of Colorado Denver (US)